Sage Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sage Therapeutics, Inc.
Data from SHORELINE’s 50mg cohort sparked mixed opinions from analysts, with some suggesting they still showed a risk-benefit profile that could challenge the drug commercially.
Founding CEO will remain involved with Alnylam’s scientific advisory board, while current president/COO Yvonne Greenstreet will move up to the chief executive’s office.
The companies will seek approval for zuranolone in MDD second-half 2022 and in PPD in first-half 2023, but that also means launch will probably happen second-half 2023.
The drug showed favorable but not significant trends across secondary endpoints, and greater efficacy in slower-progressing patients and those treated earlier in the disease, in a small subpopulation.
- Medical Devices
Drug Discovery Tools
- Drug Discovery Tools